Asparagine

Asparagine

SCHEMBL537634

C[C@H](N)C(=O)O.NC(=O)C[C@H](N)C(=O)O.NC(=O)C[C@H](N)C(=O)O.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Asparagine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 2/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
GRIK1 P39086 4/20 0.36
GRIA2 P42262 2/20 0.36
GRIA4 P48058 2/20 0.36
GRIK3 Q13003 2/20 0.36
GRIK5 Q16478 2/20 0.36
GRIK2 Q13002 2/20 0.36
GRIA1 P42261 1/20 0.36
SLC7A5 Q01650 1/20 0.35
PRCP P42785 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SLC1A1 P43005 1/20 0.33
DPP4 P27487 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Asparagine SCHEMBL4354914 1.00 NOS2 (0.37) NOS2NOS3NOS1GRIK1GRIA2
Asparagine SCHEMBL2440846 1.00 NOS2 (0.37) NOS2NOS3NOS1GRIK1GRIA2
Asparagine SCHEMBL22654326 0.96 NOS2 (0.34) NOS2NOS3NOS1GRIK1GRIA2
Asparagine SCHEMBL22654328 0.96 NOS2 (0.34) NOS2NOS3NOS1GRIK1GRIA2
Asparagine SCHEMBL2537696 0.94 NOS2 (0.41) NOS2NOS3NOS1GRIK1GRIA2
Asparagine SCHEMBL2484608 0.94 NOS2 (0.41) NOS2NOS3NOS1GRIK1GRIA2
Asparagine SCHEMBL2537700 0.94 NOS2 (0.41) NOS2NOS3NOS1GRIK1GRIA2
Asparagine SCHEMBL2484607 0.94 NOS2 (0.41) NOS2NOS3NOS1GRIK1GRIA2
Asparagine SCHEMBL28801809 0.94 NOS2 (0.41) NOS2NOS3NOS1GRIK1GRIA2
Asparagine SCHEMBL28252029 0.94 NOS2 (0.41) NOS2NOS3NOS1GRIK1GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2413953-B1 METHODS FOR PREPARING AND USING MULTICHAPERONE-ANTIGEN COMPLEXES AGENUS INC (US) 2017-11-08 EP disclosed
US-20150307567-A1 METHODS FOR PREPARING AND USING MULTICHAPERONE-ANTIGEN COMPLEXES AGENUS INC. (US) 2015-10-29 US disclosed
US-20120100173-A1 METHODS FOR PREPARING AND USING MULTICHAPERONE-ANTIGEN COMPLEXES AGENUS INC. (US) 2012-04-26 US disclosed
EP-2413953-A2 METHODS FOR PREPARING AND USING MULTICHAPERONE-ANTIGEN COMPLEXES Agenus Inc. (US) 2012-02-08 EP disclosed
WO-2010115118-A2 METHODS FOR PREPARING AND USING MULTICHAPERONE-ANTIGEN COMPLEXES ANTIGENICS, INC. (US) 2010-10-07 WO disclosed
US-20060159704-A1 Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and other infectious agents FUNDACAO OSWALDO CRUZ-FIOCRUZ (BR) 2006-07-20 US disclosed
EP-1366170-A1 USE OF FLAVIVIRUS FOR THE EXPRESSION OF PROTEIN EPITOPES AND DEVELOPMENT OF NEW LIVE ATTENUATED VACCINE VIRUS TO IMMUNE AGAINST FLAVIVIRUS AND OTHER INFECTIOUS AGENTS Fiocruz, Fundac o, Oswaldo, Cruz (BR) 2003-12-03 EP disclosed
US-20030194801-A1 Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents FUNDACAO OSWALDO CRUZ-FIOCRUZ (BR) 2003-10-16 US disclosed
WO-2002072835-A1 USE OF FLAVIVIRUS FOR THE EXPRESSION OF PROTEIN EPITOPES AND DEVELOPMENT OF NEW LIVE ATTENUATED VACCINE VIRUS TO IMMUNE AGAINST FLAVIVIRUS AND OTHER INFECTIOUS AGENTS FUNDACÃO OSWALDO CRUZ - FIOCRUZ (BR) 2002-09-19 WO disclosed
US-6113917-A GENETIC POLYPEPTIDES ADDED TO CERAMIDE BASED LIPID-GLYCAN ANCHOR STRUCTURE RMF DICTAGENE S.A. (CH) 2000-09-05 US disclosed
US-5840855-A PARATOPIC MOLECULES THAT IMMUNOREACT WITH A PEPTIDE HAVING A SPECIFIC AMINO ACID RESIDUE SEQUENCE SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1998-11-24 US disclosed
US-5658588-A Fibrinogen-coated liposomes UNIVERSITY OF CINCINNATI (US) 1997-08-19 US disclosed
EP-0305488-B1 MYCOBACTERIAL RECOMBINANTS AND PEPTIDES SCRIPPS RESEARCH INST (US) 1996-01-31 EP disclosed
US-5478726-A Mixing sample containing human lymphocytes with stimulant culture containing antigen-producing cells and peptide antigen then maintaining culture until immune cells indicate stimulation, if present, kits for medical diagnosis THE SCRIPPS RESEARCH INSTITUTE (US) 1995-12-26 US disclosed
EP-0187858-B1 PROTECTIVE PEPTIDE ANTIGEN CORRESPONDING TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN NEW YORK UNIVERSITY (US) 1992-07-08 EP disclosed
EP-0305488-A4 MYCOBACTERIAL RECOMBINANTS AND PEPTIDES 1991-06-05 EP disclosed
US-4976958-A STIMULATES T-CELLS IMMUNE TO MYCOBACTERIA SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1990-12-11 US disclosed
US-4952395-A Mycobacterial recombinants and peptides SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1990-08-28 US disclosed
EP-0305488-A1 MYCOBACTERIAL RECOMBINANTS AND PEPTIDES. SCRIPPS CLINIC RES (US) 1989-03-08 EP disclosed
WO-1988006591-A1 MYCOBACTERIAL RECOMBINANTS AND PEPTIDES SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1988-09-07 WO disclosed